Pendred syndrome is a genetic condition
characterized by congenital sensorineural hearing loss and thyroid
abnormalities resulting from a deficiency of pendrin, encoded by the SLC26A4
gene. This deficiency disrupts iodide utilization, which is necessary for
thyroid hormone synthesis, potentially leading to partial organification
defects. The hearing impairment associated with Pendred syndrome constitutes
4–10% of cases of congenital deafness, primarily due to inner ear
abnormalities. Imaging studies, such as CT and MRI may reveal modiolus
deficiency, an enlarged vestibular aqueduct, and cochlear dysplasia. A 13-year-old
girl with Pendred syndrome and a history of bilateral hearing loss since the
age of 4 years presented with goiter. (a, b) Ultrasound showing
thyroid enlargement associated with increased vascularity. (c) MRI showing vestibular
aqueduct enlargement (arrow).
In this cohort, we investigated
the mortality rate and standardized mortality ratio (SMR) among all patients
who developed type 1 diabetes at age <15 years from 1959 to 1996 in Hokkaido
Prefecture, Japan. Out of 521 enrolled patients, we analyzed the data of 391
whose attending physicians replied to our survey. Mortality rates per 100,000
person-years and SMRs were 475 and 6.9 for all patients, 559 and 8.5 for men,
and 424 and 6.0 for women, respectively. For the time of onset of type 1
diabetes, these variables were 823 and 8.8 between 1959 and 1979, 370 and 5.9
between 1980 and 1989, and 133 and 3.2 between 1990 and 1996, respectively. Mortality
rates per 100,000 person-years and SMRs were 452 and 7.3 for onset before
puberty and 514 and 6.3 for onset after puberty, respectively, and 480 and 7.1
for the acute-onset subtype and 428 and 5.6 for the incidentally detected
non-acute-onset subtype, respectively. Upon survival analysis, we observed no
difference in mortality or lifespan between the sexes. Mortality and lifespan
were not different between pre- and postpubertal onset and did not differ
between the subtypes of type 1 diabetes.
We report the case of a 7-year-old boy with
familial bilateral pheochromocytoma that recurred one year after partial
adrenalectomy. Genetic analysis revealed a novel heterozygous in-frame germline
variant in the VHL gene (NM_000551.4, c.565_585
dup, pGlu189_Gln195dup) in both the patient and his father, without any other
clinical manifestations of the von Hippel–Lindau (VHL) disease. (Upper) Family
pedigree of the proband and his parents. (Lower) Schematic representation of
the VHL gene and protein structure has been presented. The variant (red)
is located on Exon3 of the VHL gene, which encodes the Elongin C-binding
site. In-frame insertion or deletion variants may disrupt the three-dimensional
structure of the encoded proteins, particularly when
located at the Elongin C-binding site. As a result, this variant may lead to
pheochromocytomas, similar to the missense
variants. Variants affecting the Elongin-C binding site
have been associated with VHL type 2C, which is primarily presented with
pheochromocytomas.
There were no significant differences in HOMA-IR and HOMA-β between patients with MODY 2 and those with MODY 3, 1, 5. However, the majority of the patients showed mild insulin resistance and relatively sustained β-cell function. Cross mark indicates the mean value.
The study participants were divided into two groups based on their menstrual cycle patterns; patients with a regular cycle of ≤ 38 days were included in the “non-oligomenorrhea group” and others in the “oligomenorrhea group.” The results showed higher levels of serum total testosterone in both groups than in the general population, and the upper limit of normal for testosterone was set at 0.44 ng/mL. In the same patients, the total testosterone levels were significantly higher in the oligomenorrhea group than in the non-oligomenorrhea group (p = 0.033).
(Upper)
Thyroid ultrasonography revealed a nodule measuring 14 × 12 × 19 mm with clear
borders in the left lobe of the thyroid gland accompanied by cystic
degeneration and calcification without increased blood flow or surrounding lymphadenopathy.
(Lower)
The nodule shrank to 5 × 5 × 6 mm without any treatment six months after
fine-needle aspiration cytology (FNAC).